Home » Stocks » APYX

Apyx Medical Corporation (APYX)

Stock Price: $10.92 USD 0.52 (5.00%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 374.28M
Revenue (ttm) 24.71M
Net Income (ttm) -16.18M
Shares Out 34.22M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $10.92
Previous Close $10.40
Change ($) 0.52
Change (%) 5.00%
Day's Open 10.32
Day's Range 10.32 - 11.01
Day's Volume 113,565
52-Week Range 2.81 - 11.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 month ago

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...

Zacks Investment Research - 1 month ago

As of late, it has definitely been a great time to be an investor in Apyx Medical (APYX).

Zacks Investment Research - 1 month ago

Does Apyx Medical (APYX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 1 month ago

Apyx (APYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Business Wire - 1 month ago

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...

Business Wire - 2 months ago

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...

Zacks Investment Research - 2 months ago

Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Business Wire - 3 months ago

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...

Zacks Investment Research - 3 months ago

Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 3 months ago

Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Apyx (APYX) delivered earnings and revenue surprises of 18.75% and 3.33%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 3 months ago

Shares of Apyx Medical (NASDAQ:APYX) remained unaffected after the company reported Q3 results.

Business Wire - 3 months ago

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...

Business Wire - 3 months ago

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...

Business Wire - 4 months ago

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...

Zacks Investment Research - 4 months ago

Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...

Business Wire - 5 months ago

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...

Business Wire - 6 months ago

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...

Seeking Alpha - 6 months ago

Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Apyx (APYX) delivered earnings and revenue surprises of 17.65% and 71.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 6 months ago

Shares of Apyx Medical (NASDAQ:APYX) remained unaffected after the company reported Q2 results.

Business Wire - 6 months ago

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...

PRNewsWire - 7 months ago

NEW YORK, July 30, 2020 /PRNewswire/ -- WeissLaw LLP, a national class action and shareholders' rights law firm with offices in New York, California and Georgia, announces an investigation of ...

Business Wire - 8 months ago

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...

PRNewsWire - 9 months ago

PHILADELPHIA, June 6, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Apyx Medical Corporation (NASDAQ: APYX) ("Apyx" or the "Company") on behalf of the Company's stock...

PRNewsWire - 9 months ago

NEW YORK, May 29, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Apyx Medical Corpora...

Zacks Investment Research - 9 months ago

Apyx (APYX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor of Apyx Medical

Seeking Alpha - 9 months ago

Apyx Medical Corp (APYX) CEO Charlie Goodwin on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Apyx (APYX) delivered earnings and revenue surprises of 72.73% and -5.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 9 months ago

Shares of Apyx Medical (NASDAQ:APYX) were flat in pre-market trading after the company reported Q1 results.

Seeking Alpha - 11 months ago

Apyx Medical Corporation (APYX) CEO Charles Goodwin on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for November 21st

Other stocks mentioned: AMAT, ASND
Zacks Investment Research - 1 year ago

Apyx (APYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 1 year ago

Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Apyx (APYX) delivered earnings and revenue surprises of 27.78% and 13.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 1 year ago

Apyx Medical Corp (APYX) CEO Charlie Goodwin on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Apyx Medical Corporation's (APYX) CEO Charlie Goodwin on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Apyx Medical (APYX) likely to gain from J-plasma technology in Q1; margins under pressure.

About APYX

Apyx Medical Corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It markets and sells Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. The company's Renu... [Read more...]

Industry
Medical Devices
IPO Date
Jan 1, 1987
CEO
Charles Goodwin
Employees
266
Stock Exchange
NASDAQ
Ticker Symbol
APYX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Apyx Medical stock is "Buy." The 12-month stock price forecast is 12.50, which is an increase of 14.47% from the latest price.

Price Target
$12.50
(14.47% upside)
Analyst Consensus: Buy